Trial Profile
A Multicenter Phase I Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2023
Price :
$35
*
At a glance
- Drugs Ibrutinib (Primary)
- Indications Cutaneous T-cell lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions
- 08 May 2023 Status changed from active, no longer recruiting to completed.
- 08 Nov 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 08 Nov 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.